https://www.selleckchem.com/pr....oducts/danirixin.htm
3). 12-month overall survival rate was 54.6% (95% CI, 31.8-72.7). Treatment-related adverse events of grade 3 or 4 were reported in 11 (34.4%) patients. No treatment-related deaths occurred. No difference in ORR was found between patients with PD-L1 CPS greater than or equal to1 or 1; patients with high pSMAD2 level in immune cells or tumor cells had numerically higher ORR. SHR-1701 exhibits encouraging antitumor activity and controllable safety in patients with recurrent or metastatic cervical cancer after platinum-based regimens
Like
Comment
Share
